Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Sarcoma 1Gynecologic 1CNS 1

Conditions

Sarcoma, Endometrial Stromal 1Perivascular Epithelioid Cell Neoplasms 1Adenosarcoma of the uterus 1

Interventions

Paclitaxel 79Carboplatin 66pembrolizumab 61Bevacizumab 56Cisplatin 48Specimen Handling 29Drug Therapy 26Blood Specimen Collection 24Cyclophosphamide 20olaparib 19Taxes 17Magnetic Resonance Spectroscopy 16Letrozole 16Gemcitabine 16Biopsy 16liposomal doxorubicin 15niraparib 14fludarabine 14Brachytherapy 14Radiotherapy 13abemaciclib 12Topotecan 11Nivolumab 11Injections 11Doxorubicin 11lenvatinib 10Fluorouracil 10Surveys and Questionnaires 9Standard of Care 9Oxaliplatin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × RAD1901 × Gynecologic × Clear all
NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡